{"title":"迈向免疫原性热疗作用:调制电热疗","authors":"A. Szász","doi":"10.31487/j.cor.2020.09.07","DOIUrl":null,"url":null,"abstract":"Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use.\nModulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm, introduces a\nnovel, cellularly selective and immunogenic cell-ruination. The mEHT method produces tumor-vaccination,\npresenting the unharmed genetic information of cancer cells to immune cells [1]. The mEHT method is\napproved in more than 30 countries. Its phase II/III clinical applications indicate a broad perspective.","PeriodicalId":10487,"journal":{"name":"Clinical Oncology and Research","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Towards the Immunogenic Hyperthermic Action: Modulated ElectroHyperthermia\",\"authors\":\"A. Szász\",\"doi\":\"10.31487/j.cor.2020.09.07\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use.\\nModulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm, introduces a\\nnovel, cellularly selective and immunogenic cell-ruination. The mEHT method produces tumor-vaccination,\\npresenting the unharmed genetic information of cancer cells to immune cells [1]. The mEHT method is\\napproved in more than 30 countries. Its phase II/III clinical applications indicate a broad perspective.\",\"PeriodicalId\":10487,\"journal\":{\"name\":\"Clinical Oncology and Research\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Oncology and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31487/j.cor.2020.09.07\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Oncology and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31487/j.cor.2020.09.07","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Towards the Immunogenic Hyperthermic Action: Modulated ElectroHyperthermia
Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use.
Modulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm, introduces a
novel, cellularly selective and immunogenic cell-ruination. The mEHT method produces tumor-vaccination,
presenting the unharmed genetic information of cancer cells to immune cells [1]. The mEHT method is
approved in more than 30 countries. Its phase II/III clinical applications indicate a broad perspective.